Bayer Pharma Aktiengesellschaft

Stefan Joachim Jodl

Ulrich Bothe

Alexandra Rausch

Nicole Schmidt

Jörn Krätzschmar

The present application relates to substituted indazoles, to the use thereof alone or in combinations for treatment and/or prophylaxis of autoimmune disorders, and to the use thereof for production of medicaments for treatment and/or prophylaxis of autoimmune disorders, especially for treatment and/or prophylaxis of arthritides (especially psoriatic arthritis, rheumatoid arthritis, Bekhterev's disease, reactive arthritis, systematic juvenile idiopathic arthritis), systematic lupus erythematosus, multiple sclerosis, psoriasis, atopic dermatitis, allergic eczema and chronic-inflammatory bowel disorders (especially Crohn's disease and ulcerative colitis).

Growing community of inventors

Kleinmachnow, Germany

Stefan Joachim Jodl